|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product revenues, net | |||||
| Operating expenses: | |||||
| Cost of product revenues (excluding amortization of intangible assets) | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Amortization of intangible assets | |||||
| Change in fair value of deferred and contingent consideration | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Investment income | |||||
| Interest expense | |||||
| Change in fair value of interest rate swap | |||||
| Loss on extinguishment of debt | |||||
| Other (expense) income, net | |||||
| Loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Basic net loss per share (in dollars per share) | |||||
| Diluted net loss per share (in dollars per share) | |||||
| Weighted average basic common shares outstanding (in shares) | |||||
| Weighted average diluted common shares outstanding (in shares) | |||||
| Net loss, basic | |||||
| Net loss, diluted | |||||
| Other comprehensive income (loss): | |||||
| Foreign currency translation gains (losses) | |||||
| Unrealized gain on marketable securities | |||||
| Total comprehensive loss |
Loading...